Trial Profile
A Study to Evaluate the Response Durability of Rufinamide in Patients With Lennox Gastaut Syndrome (LGS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Rufinamide (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Therapeutic Use
- 04 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology